Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
REVIEW PAPER
Treatment of gout in patients after organ transplantation
Submission date: 2013-01-22
Final revision date: 2013-03-29
Acceptance date: 2013-05-09
Online publication date: 2013-06-26
Publication date: 2013-06-28
Reumatologia 2013;51(3):215-220
KEYWORDS
TOPICS
ABSTRACT
The occurrence of gout in patients undergoing organ transplantation is an important problem, often causing diagnostic and therapeutic difficulties. Hyperuricemia occurs in 5–84% and gout in 1.7–28% of patients after solid organ transplantation. In organ recipients in addition to risk factors commonly occurring in the general population there are also specific risk factors for this group such as use of diuretics or immunosuppressants and very often co-existing deterioration of renal function or function impairment in a transplanted kidney. The incidence of gout attacks depends to a large extent on the immunosuppressive treatment applied in a patient and most cases occur during the use of cyclosporine. Treatment of gouty arthritis in patients after transplantation often causes many difficulties due to significant drug interactions and the coexistence of renal failure. Mycophenolate mofetil has the best safety profile in this area. Not to be neglected is also the right choice of antihypertensive drugs.
REFERENCES (37)
1.
Griebsch A, Zöllner N. Effect of ribomononucleotides given orally on uric acid production in man. Adv Exp Med Biol 1974; 41: 443-449.
2.
Hosomi A, Nakanishi T, Fujita T, Tamai I. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS One 2012; 7: 30456. .
3.
Kahn AM, Weinman EJ. Urate transport in the proximal tubule: in vivo and vesicle studies. Am J Physiol 1985; 249: 789-798.
4.
Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-452.
5.
Majdan M. Dna moczanowa. W: Wielka Interna. Reumatologia. Puszczewicz M (red.). Medical Tribune, Warszawa 2010; 317-328.
6.
Wyngaarden JB, Kelley WN. Gout and Hyperuricemia. Grune and Stratton, New York 1976.
7.
Ifudu O, Tan CC, Dulin AL, et al. Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases. Am J Kidney Dis 1994; 23: 347-351.
8.
Abbott KC, Kimmel PL, Dharnidharka V, et al. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation 2005, 80: 1383-1391.
9.
Schwab P, Lipton S, Kerr GS. Rheumatologic sequelae and challenges in organ transplantation. Best Pract Res Clin Rheumatol 2010; 24: 329-340.
10.
Shibolet O, Elinav E, Ilan Y, et al. Reduced incidence of hyperuricemia, gout, and renal failure following liver transplantation in comparison to heart transplantation: a long-term follow-up study. Transplantation 2004; 77: 1576-1580.
11.
Neal DA, Tom BD, Gimson AE, et al. Hyperuricemia, gout, and renal function after liver transplantation. Transplantation 2001; 72: 1689-1691.
12.
Wluka AE, Ryan PF, Miller AM, et al. Post-cardiac transplantation gout: incidence of therapeutic complications. J Heart Lung Transplant 2000; 19: 951-956.
13.
Cohen M, Cohen E. Enthesopathy and atypical gouty arthritis following renal transplantation: a case controlled study. Rev Rhum Engl Ed 1995; 62: 86-90.
14.
Peeters P, Sennesael J. Low-back pain caused by spinal tophus – a complication of gout in a kidney transplant recipient. Nephrol Dial Transplant 1998; 13: 3245-3247.
15.
Chang PC, Seeger LL, Motamedi K, Chan JB. Tophaceous gout of the first costochondral junction in a heart transplant patient. Skeletal Radiol 2006; 35: 684-686.
16.
Noordzij TC, Leunissen KM, Van Hooff JP. Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use. Transplantation 1991; 52: 64-67.
17.
Lin HY, Rocher LL, McQuillan MA, et al. Cyclosporine-induced hy-peruricemia and gout. N Engl J Med 1989; 321: 287-292.
18.
Zimmermann-Górska I. Postępowanie diagnostyczno-terapeutyczne w chorobach wywołanych przez kryształy. Reumatologia 2012; 50: 177-180.
19.
Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324.
20.
Simkin PA, Gardner GC. Colchicine use in cyclosporine treated transplant recipients: how little is too much? J Rheumatol 2000; 27: 1334-1337.
21.
Eleftheriou G, Bacis G, Fiocchi R, Sebastiano R. Colchicine-induced toxicity in a heart transplant patient with chronic renal failure. Clin Toxicol (Phila) 2008; 46: 827-830.
22.
Gutkowski K, Hartleb M. Zastosowanie azatiopryny i 6-merkaptopuryny w leczeniu nieswoistych chorób zapalnych jelit. Przegl Gastroenterol 2009; 4: 225-230.
23.
Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006; 33: 1646-1650.
25.
Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 1999; 5: 49-55.
26.
Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306: 711-720.
27.
American College of Rheumatology Hotline: Pegloticase and concomitant urate-lowering therapies. http://www.rheumatology.org/pu....
28.
Direz G, Noël N, Guyot C, et al. Efficacy but side effects of anakinra therapy for chronic refractory gout in a renal transplant recipient with preterminal chronic renal failure. Joint Bone Spine 2012; 79: 28-34.
29.
So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010; 62: 3064-3076.
30.
Schumacher HR, Sundy JS, Terkeltaub RL, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012; 64: 876-884.
31.
Hueskes BA, Roovers EA, Mantel-Teeuwisse AK, et al. Use of diuretics and the risk of gouty arthritis: a systematic review. Semin Arthritis Rheum 2012; 41: 879-889.
32.
Soffer BA, Wright JT Jr, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-117.
33.
Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000; 22: 1186-1203.
34.
Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343-1351.
35.
Würzner G, Gerster JC, Chiolero A, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19: 1855-1860.
36.
Dang A, Zhang Y, Liu G, et al. Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population. J Hum Hypertens 2006; 20: 45-50.
37.
Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012; 12: 344:d8190.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
